I agree that TRCA's PR is to let someone out of stock. p=0.48 or 48% or 48 every 100 is too big. This is not a good number to bragging about. However, it does provide good prospect for iPlex.
An additional analysis of hypoglycemic safety was also provided by Tercica. In 22 patients with severe Primary IGFD, up to four times daily blood glucose measurements were made before and for up to seven days after initiation of Increlex treatment. The results showed no statistically significant difference in the frequency of hypoglycemia observed before versus after the start of Increlex (7.0% and 8.8%, respectively; p=0.48).
Market Data 
Markets 
AI
